Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Abnormal Peri-organ-Intra-organ Fat (APIFat) and Rheumatoid Arthritis: An Under-investigated Link for Increased Cardiovascular Risk?

Author(s): Niki Katsiki*, Dimitri P. Mikhailidis and Christos Mantzoros

Volume 18, Issue 3, 2020

Page: [249 - 253] Pages: 5

DOI: 10.2174/1570161117999190802150857

« Previous Next »
[1]
Lauper K, Gabay C. Cardiovascular risk in patients with rheumatoid arthritis. Semin Immunopathol 2017; 39(4): 447-59.
[http://dx.doi.org/10.1007/s00281-017-0632-2] [PMID: 28455580]
[2]
Blum A, Adawi M. Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 2019; 18(7): 679-90.
[http://dx.doi.org/10.1016/j.autrev.2019.05.005] [PMID: 31059840]
[3]
Reiss AB, Silverman A, Khalfan M, et al. Accelerated atherosclerosis in rheumatoid arthritis: mechanisms and treatment. Curr Pharm Des 2019; 25(9): 969-86.
[http://dx.doi.org/10.2174/1381612825666190430113212] [PMID: 31208307]
[4]
Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 2015; 10(2) e0117952
[http://dx.doi.org/10.1371/journal.pone.0117952] [PMID: 25689371]
[5]
Jagpal A, Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol 2018; 2: 10.
[http://dx.doi.org/10.1186/s41927-018-0014-y] [PMID: 30886961]
[6]
Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74(3): 480-9.
[http://dx.doi.org/10.1136/annrheumdis-2014-206624] [PMID: 25561362]
[7]
Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2018; 77(1): 98-103.
[http://dx.doi.org/10.1136/annrheumdis-2017-211836] [PMID: 28970215]
[8]
Clavel G, Sigaux J, Semerano L. Is fat that bad in rheumatoid arthritis? Joint Bone Spine 2019; 86(2): 129-30.
[http://dx.doi.org/10.1016/j.jbspin.2018.06.007] [PMID: 30025960]
[9]
Yoshida T, Hashimoto M, Kawahara R, et al. Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int 2018; 38(9): 1679-89.
[http://dx.doi.org/10.1007/s00296-018-4095-0] [PMID: 29974186]
[10]
Alvarez-Nemegyei J, Buenfil-Rello FA, Pacheco-Pantoja EL. Association between body composition and disease activity in rheumatoid arthritis. A systematic review. Reumatol Clin 2016; 12(4): 190-5.
[http://dx.doi.org/10.1016/j.reuma.2015.09.001] [PMID: 26549160]
[11]
Kerekes G, Nurmohamed MT, González-Gay MA, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol 2014; 10(11): 691-6.
[http://dx.doi.org/10.1038/nrrheum.2014.121] [PMID: 25090948]
[12]
Katsiki N, Athyros VG, Mikhailidis DP. Abnormal peri-organ or intra-organ fat (APIFat) deposition: An underestimated predictor of vascular risk? Curr Vasc Pharmacol 2016; 14(5): 432-41.
[http://dx.doi.org/10.2174/1570161114666160722112738] [PMID: 27456108]
[13]
Katsiki N, Dimitriadis G, Mikhailidis DP. Perirenal adiposity and other excessive intra- and peri-organ fat depots: what is the connection? Angiology 2019; 70(7): 581-3.
[http://dx.doi.org/10.1177/0003319719848204] [PMID: 31064196]
[14]
Lau WB, Ohashi K, Wang Y, et al. Role of Adipokines in cardiovascular disease. Circ J 2017; 81(7): 920-8.
[http://dx.doi.org/10.1253/circj.CJ-17-0458] [PMID: 28603178]
[15]
Giudice J, Taylor JM. Muscle as a paracrine and endocrine organ. Curr Opin Pharmacol 2017; 34: 49-55.
[http://dx.doi.org/10.1016/j.coph.2017.05.005] [PMID: 28605657]
[16]
Santo RCE, Fernandes KZ, Lora PS, Filippin LI, Xavier RM. Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2018; 9(5): 816-25.
[http://dx.doi.org/10.1002/jcsm.12320] [PMID: 30133186]
[17]
Iannone F, Lopalco G, Rigante D, Orlando I, Cantarini L, Lapadula G. Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmun Rev 2016; 15(5): 447-50.
[http://dx.doi.org/10.1016/j.autrev.2016.01.010] [PMID: 26808074]
[18]
Wolfe F, Michaud K. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64(10): 1471-9.
[http://dx.doi.org/10.1002/acr.21627] [PMID: 22514152]
[19]
van der Helm-van Mil AHM, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008; 67(6): 769-74.
[http://dx.doi.org/10.1136/ard.2007.078832] [PMID: 17965124]
[20]
Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One 2018; 13(5) e0195123
[http://dx.doi.org/10.1371/journal.pone.0195123] [PMID: 29771924]
[21]
Giles JT, Allison M, Blumenthal RS, et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010; 62(11): 3173-82.
[http://dx.doi.org/10.1002/art.27629] [PMID: 20589684]
[22]
Katsiki N, Mikhailidis DP. Abnormal peri-organ or intra-organ fat deposition and vascular risk. Angiology 2018; 69(10): 841-2.
[http://dx.doi.org/10.1177/0003319718776528] [PMID: 29783853]
[23]
Ngeuleu A, Allali F, Medrare L, Madhi A, Rkain H, Hajjaj-Hassouni N. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int 2017; 37(6): 1015-20.
[http://dx.doi.org/10.1007/s00296-017-3665-x] [PMID: 28258473]
[24]
Masuko K. Rheumatoid cachexia revisited: a metabolic co-morbidity in rheumatoid arthritis. Front Nutr 2014; 1: 20.
[http://dx.doi.org/10.3389/fnut.2014.00020] [PMID: 25988122]
[25]
Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 2010; 6(8): 445-51.
[http://dx.doi.org/10.1038/nrrheum.2010.105] [PMID: 20647995]
[26]
Kontny E, Zielińska A, Skalska U, Księżopolska-Orłowska K, Głuszko P, Maśliński W. Distinct secretory activity and clinical impact of subcutaneous abdominal adipose tissue in women with rheumatoid arthritis and osteoarthritis. Inflammation 2017; 40(1): 106-16.
[http://dx.doi.org/10.1007/s10753-016-0459-3] [PMID: 27796618]
[27]
Ursini F, Russo E, Mauro D, et al. Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study. Eur J Clin Invest 2017; 47(10): 728-35.
[http://dx.doi.org/10.1111/eci.12798] [PMID: 28796299]
[28]
Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? Semin Arthritis Rheum 2016; 46(3): 291-304.
[http://dx.doi.org/10.1016/j.semarthrit.2016.05.012] [PMID: 27388027]
[29]
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019; 92: 82-97.
[http://dx.doi.org/10.1016/j.metabol.2018.11.014] [PMID: 30502373]
[30]
Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17-32.
[http://dx.doi.org/10.1016/j.metabol.2017.02.014] [PMID: 28521870]
[31]
Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8): 1109-23.
[http://dx.doi.org/10.1016/j.metabol.2016.05.003] [PMID: 27237577]
[32]
Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ - linking NAFLD and insulin resistance. Endocr Rev 2019; 40(5): 1367-93.
[http://dx.doi.org/10.1210/er.2019-00034] [PMID: 31098621]
[33]
Sakthiswary R, Chan GY, Koh ET, Leong KP, Thong BY. Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. ScientificWorldJournal 2014; 2014 823763
[http://dx.doi.org/10.1155/2014/823763] [PMID: 24971392]
[34]
Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 2013; 28(4): 458-63.
[http://dx.doi.org/10.1097/HCO.0b013e3283605fba] [PMID: 23591557]
[35]
Turan Y. The nonalcoholic fatty liver disease fibrosis score is related to epicardial fat thickness and complexity of coronary artery disease. Angiology 2020; 71(1): 77-82.
[PMID: 31018673]
[36]
Lima-Martínez MM, Campo E, Salazar J, et al. Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies. Arthritis 2014; 2014 782850
[http://dx.doi.org/10.1155/2014/782850] [PMID: 25574390]
[37]
Ormseth MJ, Lipson A, Alexopoulos N, et al. Association of epicardial adipose tissue with cardiometabolic risk and metabolic syndrome in patients with rheumatoid arthritis. Arthritis Care Res 2013; 65(9): 1410-5.
[http://dx.doi.org/10.1002/acr.22027] [PMID: 23592527]
[38]
Temiz A, Gökmen F, Gazi E, et al. Epicardial adipose tissue thickness, flow-mediated dilatation of the brachial artery, and carotid intima-media thickness: Associations in rheumatoid arthritis patients. Herz 2015; 40(Suppl. 3): 217-24.
[http://dx.doi.org/10.1007/s00059-014-4140-z] [PMID: 25139185]
[39]
Pi H, Zhou H, Jin H, Ning Y, Wang Y. Abnormal glucose metabolism in rheumatoid arthritis. BioMed Res Int 2017; 2017 9670434
[http://dx.doi.org/10.1155/2017/9670434] [PMID: 28529957]
[40]
Nicolau J, Lequerré T, Bacquet H, Vittecoq O. Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine 2017; 84(4): 411-6.
[http://dx.doi.org/10.1016/j.jbspin.2016.09.001] [PMID: 27777170]
[41]
Garcia TS, Rech TH, Leitão CB. Pancreatic size and fat content in diabetes: A systematic review and meta-analysis of imaging studies. PLoS One 2017; 12(7) e0180911
[http://dx.doi.org/10.1371/journal.pone.0180911] [PMID: 28742102]
[42]
Sanna F, Margaritis M, Antoniades C. Perivascular adipose tissue as an endocrine organ: the role of statins. Curr Pharm Des 2017; 23: 7055-60.
[PMID: 28950824]
[43]
Hollan I, Meroni PL, Ahearn JM, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013; 12(10): 1004-15.
[http://dx.doi.org/10.1016/j.autrev.2013.03.013] [PMID: 23541482]
[44]
Baker JF, Mostoufi-Moab S, Long J, et al. Intramuscular fat accumulation and associations with body composition, strength, and physical functioning in patients with rheumatoid arthritis. Arthritis Care Res 2018; 70(12): 1727-34.
[http://dx.doi.org/10.1002/acr.23550] [PMID: 29481721]
[45]
Chung HS, Choi KM. Adipokines and Myokines: A pivotal role in metabolic and cardiovascular disorders. Curr Med Chem 2018; 25(20): 2401-15.
[http://dx.doi.org/10.2174/0929867325666171205144627] [PMID: 29210643]
[46]
Liu BX, Sun W, Kong XQ. Perirenal fat: a unique fat pad and potential target for cardiovascular disease. Angiology 2019; 70(7): 584-93.
[PMID: 30301366]
[47]
Wang H, Leng Y, Gong Y. Bone marrow fat and hematopoiesis. Front Endocrinol (Lausanne) 2018; 9: 694.
[http://dx.doi.org/10.3389/fendo.2018.00694] [PMID: 30546345]
[48]
Möller B, Scherer A, Förger F, Villiger PM, Finckh A. Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Ann Rheum Dis 2014; 73(4): 691-6.
[http://dx.doi.org/10.1136/annrheumdis-2012-202709] [PMID: 23505235]

Rights & Permissions Print Cite
Article Metrics
9
1
© 2024 Bentham Science Publishers | Privacy Policy